What happened
C&R Research disclosed a supply contract with Daewoong Pharmaceutical, worth US$7.59M, about 17.71% of its recent annual revenue, running through Mar 2029.
For context, this single contract equals about 17.71% of the company's most recent annual revenue.
| Counterparty | Daewoong Pharmaceutical |
|---|---|
| Contract value | US$7.59M |
| vs. recent revenue | 17.71% |
| Through | Mar 2029 (from Mar 2026) |
| Filed | 2026-03-30, Supply contract signed |
| Source | DART rcept 20260330900545 → open original filing |
Source: DART. Information only, not investment advice.